When to Give Bijuva
Bijuva should be given to postmenopausal women with an intact uterus who have moderate-to-severe vasomotor symptoms (hot flashes and night sweats) and no contraindications to systemic estrogen-progestogen therapy. 1
Specific Indications
Bijuva (estradiol/progesterone combination capsule) is FDA-approved specifically for women who meet ALL of the following criteria:
- Have a uterus (the progesterone component provides endometrial protection) 1
- Moderate-to-severe vasomotor symptoms due to menopause 1
- No contraindications to systemic hormone therapy 1
Absolute Contraindications to Bijuva
Do NOT give Bijuva if the patient has any of the following 1:
- Undiagnosed abnormal genital bleeding
- Breast cancer (current or history)
- Estrogen-dependent neoplasia
- Active DVT, PE, or history of these conditions
- Active arterial thromboembolic disease (stroke, MI) or history
- Known anaphylactic reaction, angioedema, or hypersensitivity to Bijuva
- Hepatic impairment or disease
- Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
Optimal Timing Window
The ideal candidate is a woman who is within 10 years of menopause onset or younger than 60 years of age. 2 This timing window is critical because post-hoc analyses from the Women's Health Initiative and observational data suggest that benefits exceed risks in this population, whereas older women (average age 63 in WHI) showed risks disproportionate to benefits 2.
Dosing
Give one capsule orally each evening with food. 1 Available strengths are:
- 1 mg estradiol/100 mg progesterone (the FDA-approved dose that showed efficacy) 3
- 0.5 mg estradiol/100 mg progesterone 1
The 1 mg/100 mg dose demonstrated significant reductions in vasomotor symptom frequency and severity at both 4 and 12 weeks compared to placebo, with 82-88% of women achieving clinically meaningful improvement (≥25 moderate-to-severe VMS reduction weekly) 4, 5.
Clinical Context
Bijuva represents the first FDA-approved bioidentical combination product containing both 17β-estradiol and progesterone in a single capsule 6. This is particularly relevant for women who prefer bioidentical hormones but want to avoid unregulated compounded hormone therapy 3, 5. The REPLENISH trial demonstrated no cases of endometrial hyperplasia over 52 weeks, confirming adequate endometrial protection 6, 5.
Key Safety Considerations
While managing patients on Bijuva, monitor for:
- Cardiovascular events: Increased risks of PE, DVT, stroke, and MI are reported with estrogen-plus-progestin therapy 1
- Breast cancer surveillance: Perform regular breast examinations and mammography 1
- Thyroid function: Monitor in women on thyroid replacement therapy 1
The evidence suggests that natural progesterone may be associated with reduced breast cancer risk compared to synthetic progestins, though data remain insufficient for firm conclusions 2.